Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurocrine grants Dainippon indiplon rights for Japan

NBIX granted Dainippon Sumitomo (Tokyo:4506; Osaka:4506) exclusive rights to develop and commercialize indiplon in Japan.

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE